Related Experiment Video
Updated: Jan 11, 2026
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Efficacy and Safety of Anti-Influenza Drugs in 160 Chinese Children With Influenza A: A Retrospective Study
1Department of Pediatrics, China-Japan Friendship Hospital, Beijing, China.
Insights
Baloxavir marboxil demonstrated superior efficacy in treating influenza A in children, significantly reducing fever and illness duration compared to oseltamivir. Oseltamivir capsules were the most cost-effective, while granules offered more accurate dosing.
Area of Science:
- Pediatric Infectious Diseases
- Antiviral Therapeutics
- Influenza A Treatment
Background:
- Influenza A poses a significant health burden in pediatric populations.
- Baloxavir marboxil and oseltamivir (capsules and granules) are key antiviral treatments.
- Real-world comparative data on these treatments in Chinese children is limited.
Purpose of the Study:
- To comprehensively analyze the therapeutic efficacy and safety of baloxavir marboxil versus oseltamivir phosphate (capsules and granules).
- To evaluate treatment outcomes in 160 Chinese children diagnosed with influenza A.
- To compare clinical characteristics, treatment effects, drug costs, and adverse reactions.
Main Methods:
- Retrospective study of 160 children (aged 10-16) with influenza A treated between January 2023 and August 2024 in Beijing.
- Participants were divided into three groups: baloxavir (n=49), oseltamivir capsules (n=56), and oseltamivir granules (n=55).
- Comparison of fever clearance time, total illness duration, curative rate, drug costs, and adverse events.
Main Results:
- Baloxavir group showed significantly shorter fever clearance time and total illness duration, especially in children with high fever (p<0.01).
- Baloxavir achieved a higher curative rate (84%) compared to oseltamivir capsules (45%) and granules (49%) (p<0.01).
- Oseltamivir capsules were the most cost-effective; baloxavir was slightly less costly than oseltamivir granules (p<0.01).
Conclusions:
- Baloxavir marboxil demonstrates superior efficacy in reducing fever and shortening illness duration in pediatric influenza A.
- Single-dose baloxavir enhances treatment compliance but is a more expensive option.
- Oseltamivir capsules offer the best cost-effectiveness, while granules allow for more precise dosing.
Aim:
In this study, we aimed to provide a comprehensive analysis of real-world implications for the therapeutic efficacy and safety of baloxavir marboxil, oseltamivir phosphate capsules and oseltamivir phosphate granules in the treatment of 160 Chinese children with influenza A.
Methods:
This retrospective study included children aged 10-16 with influenza A treated at a hospital in Beijing between January 2023 and August 2024. Participants were categorised into three groups: oseltamivir capsule group (n = 56), oseltamivir granule group (n = 55) and baloxavir group (n = 49). Clinical characteristics, epidemiology, therapeutic effects (e.g., fever clearance time, total illness duration and curative rate), drug costs and adverse reactions were compared among groups.
Results:
No significant differences were found in demographics or initial symptoms (p > 0.05). Fever clearance time and total illness duration were significantly shorter in the baloxavir group compared to the oseltamivir capsule group (both p < 0.01) and the oseltamivir granule group (p < 0.01, p < 0.05) mainly in children with high fever. While the total effective rates were similar across groups, baloxavir showed a notably higher curative rate (84%, 41/49) than oseltamivir capsules (45%, 25/56) and granules (49%, 27/55) (p < 0.01). Cost analysis indicated that oseltamivir capsules were the least expensive, with baloxavir being slightly less costly than oseltamivir granules (p < 0.01).
Conclusions:
Baloxavir marboxil exhibited superior efficacy in reducing fever and shortening the illness duration. Its single-dose regimen enhances compliance with antiviral therapy, although it remains a relatively more expensive option. In contrast, oseltamivir granules enabled more accurate dosing, while oseltamivir capsules were the most cost-effective treatment.
More Related Videos
07:07Evaluation of T Follicular Helper Cells and Germinal Center Response During Influenza A Virus Infection in Mice
Published on: June 27, 2020
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
